Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Buildings Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Dividends payables Goodwill Goodwill & Intangibles Intangibles Land & Improvements Liabilities and Shareholders Equity Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Altimmune (ALT) Short term Debt (2021 - 2022)

Historic Short term Debt for Altimmune (ALT) over the last 8 years, with Q1 2022 value amounting to $4.3 million.

Altimmune's Short term Debt changed N/A to $4.3 million in Q1 2022 from the same period last year, while for Mar 2022 it was $4.3 million, marking a year-over-year change of. This contributed to the annual value of $6.1 million for FY2021, which is N/A changed from last year.
According to the latest figures from Q1 2022, Altimmune's Short term Debt is $4.3 million.
In the past 5 years, Altimmune's Short term Debt ranged from a high of $6.1 million in Q4 2021 and a low of $4.3 million during Q1 2022